Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes.
Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He has received grant/research support from Elli Lilly, Novo Nordisk and Boehringer Ingelheim. On the advisory board for Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He has received honoraria/honorarium from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He is a Speaker’s Bureau participant with Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of ADA 2023.
